Delayed Introduction of Tacrolimus Postliver Transplant With Intravenous Mycophenolate Mofetil Preserves Renal Function Without Incurring Rejection
I n most liver recipients, tacrolimus is used as a primary immunosuppressive agent, which has both an acute and a chronic nephrotoxic effect. Renal dysfunction has a significant impact on survival outcome after liver transplantation (LTx). Mycophenolate mofetil (MMF) has no known nephrotoxicity. The absorption of oral formulation of MMF is reported to be more than 90% in healthy volunteers, kidney, heart, and lung transplant recipients (1Y3). The absorption of oral MMF was not studied in immediate post-LTx until 2007 (4) .
We have previously shown that after LTx, the trough concentration of mycophenolic acid rises with time (5) . Furthermore, after LTx, we have shown an improvement in the bioavailability of oral MMF overtime (5, 6) . Subsequently, we have demonstrated that oral absorption of MMF in the second week after LTx is only 48% (4), this potentially being even lower in the first week after LTx. In previously reported 130 patients, the rate of acute rejection was 6.1% with the use of intravenous (IV) MMF. Acute rejections were easily reversed with methyl prednisolone (7) .
The aim of our study is to examine the number of days tacrolimus introduction could be delayed after LTx, to preserve the renal function while avoiding rejection, by using IV MMF. This is a retrospective study from a newly started, small volume LTx program, with close monitoring. From February 2009 to July 2012, 70 patients underwent LTx. There were 51 men and 19 women with a mean age of 54.5T9.5 years. Forty-eight (68.5%) patients were infected with hepatitis C virus (HCV), and 17 patients (24.2%) had ethanol induced cirrhosis. Twentyeight of these (40%) had hepatocellular carcinoma (HCC).
Management of immunosuppression in pretransplant phase was identical for all patients. In the pretransplant phase; all patients received induction with single oral dose of tacrolimus 0.03 to 0.05 mg/kg given on call to surgery, IV MMF 1 g infused over 2 hr with the start of surgery and MP 500 mg IV in anhepatic phase. We preferred this approach based on the theory of tolerogenic immunosuppression for organ transplantation where recipients pretreatment allows posttransplant minimal immunosuppression (8) . In the posttransplant phase, subsequent introduction of tacrolimus was gradually delayed from 1 to 5 days after the LTx as the program matured with progression based on prior observations, renal function, hepatic function, and mental status. All patients received IV MMF 1 g infused over 2 hr twice per day for 4 to 7 days after LTx. Two days after whole blood tacrolimus trough concentrations were greater than 5 ng/mL, IV MMF rout was switched to oral. A standard total dose of 600 mg MP was tapered over 5 days (50 mg every 6 hr, four doses; then 40 mg every 6 hr, four doses; then 30 mg every 6 hr, four doses; then 20 mg every 6 hr, four doses; then 20 mg every 12 hr, two doses) (Fig. 1 ). On day 6, a daily maintenance oral dose of 20 mg prednisone was started and reduced to 15 mg by postoperative day 15. Subsequent reduction in the dosage of all three immunosuppressive agents were made as clinically indicated.
The introduction of tacrolimus after LTx was progressively delayed as our experience grew with this novel approach; for the first 16 cases (February 2009 to December 2009), in two patients (12.5%), tacrolimus introduction was delayed for 2 days after LTx. In the next 28 patients (January 2010 to July 2011), tacrolimus introduction was delayed in 26 of these patients (92.7%) for 1 to 5 days after transplantation. In the last 26 patients, tacrolimus introduction was delayed in all cases (100%) for 2 to 5 days. Thus, of the last 54 patients, tacrolimus introduction was delayed in 52 patients (96.3%) for 1 to 5 days after LTx. The goals for tacrolimus trough level were: 9 5 ng/mL by postoperative day 6, and 6 to 8 ng/mL in the second week after LTx.
All patients were followed up for 1 year from the transplant. Patient survival, graft survival, causes of death, causes of graft loss, rate of rejection, and renal function were examined.
One year actual patient survival was 88.6%. Eight (11.4%) patients died from recurrent HCC (n=2), myocardial infarction (n=2), sepsis (n=2), one each from recurrent hepatitis C virus infection, and withdrawal of support with functioning allograft.
One year actual graft survival was 86.5%. Four (5.7%) patients required retransplantation, three for primary nonfunction and one for early fibrosing cholestatic hepatitis. Two of these four patients survived after retransplantation.
Thirty-three patients underwent 87 liver biopsies as clinically indicated. Protocol biopsies were not performed. Rejection was diagnosed only in two recipients. One patient (27-year-old woman) experienced moderate to severe acute cellular rejection (ACR); rejection activity index was 6, 4 months after transplant. She was noncompliant for her medications and clinic visits. She had undetectable tacrolimus levels for several weeks before rejection. She responded to MP 1.5 g total dose spread over 4 days without antibody use. Another patient (37-year-old man) experienced severe ACR (rejection activity index=8) on postoperative day 8. The rejection was reversed with MP 2 g total dose spread over 5 days and antibody preparation was not required.
Renal function was examined in three groups of patients based on preLTx renal function. Group I patients were on renal replacement therapy (RRT), group II patients had severe renal dysfunction not on RRT (serum creatinine 93.0 mg/dL), and group III were the remaining patients (serum creatinine G3.0 mg/dL).
Group I patients (n=9, 12.8%) were on hemodialysis for 1 to 14 weeks before LTx. Of these patients, one died at home after discharge from myocardial infarction, whereas all remaining eight recipients were alive at 12 months after LTx without RRT. Dialysis regimen and serum creatinine in each patient are shown in Table 1 . During the early part of the program in first four patients, introduction of tacrolimus was not delayed and RRT after LTx varied from 1 to 7 dialysis sessions. In last five patients, tacrolimus induction was delayed for 2 to 4 days, and dialysis requirement was zero to nine sessions. Incidentally, one patient who was on dialysis for 14 weeks before LTx required one dialysis session after LTx.
Group II patients (n=11, 15.7%) had severe renal dysfunction at the time of LTx without requiring RRT. Serum creatinine and the delay in tacrolimus introduction are shown in Table 2 (top). Mean serum creatinine before LTx was 3.91T0.79 mg/dL and 1.86T1.24 mg/dL at 12 months after LTx. None of the LTx recipients required dialysis, except one who was commenced on hemodialysis 4 months and 12 days after retransplantation. Unfortunately, after 6 weeks of hemodialysis, support was withdrawn by the family. Another patient died from metastatic recurrence of HCC.
Group III patients (remaining 50 cases) with normal to moderate renal dysfunction had mean serum creatinine 1.1T0.51 mg/dL before LTx which remained stable up to 3 months (1.05T0.3 mg/dL) and increased to 1.32T1.12 mg/dL at 12 months after LTx. Mean serum creatinine for group III at various time intervals before and after LTx is given in Table 2 (bottom). One patient, who received IV contrast for a pulmonary angiogram 2 days after retransplant, required RRT for 1 week.
All patients tolerated IV MMF. Discontinuation of IV MMF was not required in any patient for known side effects of diarrhea, gastrointestinal intolerance, or leukopenia.
In conclusion, use of pre-LTx induction with single dose of oral tacrolimus, 1 g IV MMF and 500 mg MP, followed by IV MMF posttransplant and 600 mg MP taper over 5 days provide adequate immunosuppression, without the risk of acute rejection. This allows a delay of up to 4 days in tacrolimus introduction after LTx. This regimen provides a beneficial effect on the recovery of renal function in patients with renal impairment or renal failure before LTx and after LTx, reducing the risk of renal dysfunction and new onset dialysis, without the use of any antibody preparation.
Because the completion of the present study, we have treated 17 more patients with IV MMF and 4 days delay in introduction of tacrolimus without ACR. This immunosuppressive strategy has become the standard of care at out LTx center. 
